ACHE and early-onset autosomal dominant Alzheimer disease: Bioactive peptides represent a promising therapeutic approach for Alzheimer’s disease (AD) by maintaining cholinergic system homeostasis through the inhibition of acetylcholinesterase (AChE) activity.